ORIGINALINVESTIGATION
Effects of Calcium Supplementation
on Clinical Fracture and Bone Structure
Results of a 5-Year, Double-blind, Placebo-Controlled Trial in Elderly Women
RichardL.Prince,MD;AmandaDevine,PhD;SatvinderS.Dhaliwal,MSc;IanM.Dick,PhD
Background:Increaseddietarycalciumintakehasbeen analysis,calciumsupplementationdidnotsignificantlyre-
proposedasapopulation-basedpublichealthinterven- ducefracturerisk(hazardratio,0.87;95%confidencein-
tion to prevent osteoporotic fractures. We have exam- terval,0.67-1.12).However,830patients(56.8%)whotook
inedwhethercalciumsupplementationdecreasesclini- 80%ormoreoftheirtablets(calciumorplacebo)peryear
calfractureriskinelderlywomenanditsmechanismof hadreducedfractureincidenceinthecalciumcompared
action. withtheplacebogroups(10.2%vs15.4%;hazardratio,
0.66; 95% confidence interval, 0.45-0.97). Calcium-
Methods:Five-year,double-blind,placebo-controlled treatedpatientshadimprovedquantitativeultrasonogra-
studyof1460womenrecruitedfromthepopulationand phyfindingsoftheheel,femoralneckandwhole-bodydual
olderthan70years(meanage,75years)whowereran- x-rayabsorptiometrydata,andbonestrengthcompared
domizedtoreceivecalciumcarbonate,600mgtwiceper withplacebo-treatedpatients.Ofthe92000adverseevents
day, or identical placebo. The primary end points in- recorded,constipationwastheonlyeventincreasedbythe
cluded clinical incident osteoporotic fractures, verte- treatment(calciumgroup,13.4%;placebogroup,9.1%).
braldeformity,andadverseeventsascertainedin5years.
Bonestructurewasalsomeasuredusingdualx-rayab- Conclusion:Supplementationwithcalciumcarbonatetab-
sorptiometryofthehipandwholebody,quantitativeul- letssupplying1200mg/disineffectiveasapublichealthin-
trasonography of the heel, and peripheral quantitative terventioninpreventingclinicalfracturesintheambulatory
computedtomographyofthedistalradius. elderlypopulationowingtopoorlong-termcompliance,
butitiseffectiveinthosepatientswhoarecompliant.
Results:Amongourpatients,16.1%sustained1ormore
clinical osteoporotic fractures. In the intention-to-treat ArchInternMed.2006;166:869-875
R
ECENT CLINICAL, ANIMAL, cium supplementation in a relatively
andcellstudieshavecon- healthy,vitaminD–sufficient,andambu-
firmed that an important latory elderly population in which the
physiological effect of es- wholepopulationratherthanthosewith
trogen is increased cal- low bone mass were studied. The study
ciumtransportacrossthebowelwalland alsoexaminesthebiochemicalandstruc-
kidneytubule.1,2Thus,thereductionincir- turaleffectsofcalciumsupplementation
culating estrogen concentration after toprovideanunderstandingofthemecha-
AuthorAffiliations:Schoolof menopauseresultsinasmalldailynega- nismoftheeffectonfracturereduction.
MedicineandPharmacology, tive calcium balance.3 This negative cal-
UniversityofWesternAustralia cium balance can be partly corrected by METHODS
(DrsPrince,Devine,andDick),
increasingdietarycalciumintakeasdem-
WesternAustralianInstituteof
onstratedbythebeneficialeffectsofcal-
MedicalResearch(DrsPrince, PATIENTS
ciumsupplementationonbonedensityin
Devine,andDick),Schoolof
PublicHealth,Curtin postmenopausal women.3-7 The unre- Werecruited1460womenduring1yearusing
UniversityofTechnology solved critical issue for patient care is apopulation-basedapproachinwhicharan-
(MrDhaliwal),andSchoolof whethertheeffectsizeissufficienttore- domselectionofwomen(n=24800)olderthan
Exercise,BiomedicalandHealth duceclinicalfracturerates. 70yearsontheelectoralrollinWesternAus-
Science,EdithCowan Reducing the population risk of frac- traliareceivedaletterinvitingthemtojointhe
University(DrDevine),Perth, study.Ofthese,4312individualsrespondedand
tureislikelytorequireapublichealthin-
andDepartmentof werecontactedbytelephone(Figure1).More
terventionforallinadditiontotreatment
EndocrinologyandDiabetes, than98%ofwomenofthisageareontheelec-
ofhigh-riskindividualswithpharmaceu-
SirCharlesGairdnerHospital, toralroll(n=33366).Althoughthepatientsen-
Nedlands(DrsPrince,Devine, tical intervention.8 Therefore, the cur- teringthestudywereweightedinfavorofthose
andDick),Australia. rentstudywasplannedasastudyofcal- inhighersocioeconomiccategories,diseasebur-
(REPRINTED)ARCHINTERNMED/VOL166, APR24,2006 WWW.ARCHINTERNMED.COM
869
©2006AmericanMedicalAssociation.Allrightsreserved.
Downloaded From: http://archinte.jamanetwork.com/ by a Fudan University User on 05/11/2015
sitywasmeasuredatthehipandwholebodyonafan-beam
densitometer(HologicAcclaim4500A;HologicCorp,Waltham,
4312Underwent Screening
Mass)at1and5years.TheCVsatthetotalhip,femoralneck,
andwholebodywere1.2%,1.4%,and0.8%,respectively.18Pe-
1222Excluded
ripheralquantitativecomputedtomographybonestructureand
densityweremeasuredintheradiusatasite4%ofthelength
1580Not Interested
oftheradiusdistaltothewristjoint,usingaperipheralquan-
titative computed tomography device (XCT-2000; StraTec
1510Eligible
MedizintechnikGmbH,Pforzheim,Germany).Thevoxelsize
wassetat150µminthexandydirectionsand1000µminthe
81(11.1%) 84(11.5%)
Withdrew Withdrew zdirection.TheCVsfortrabecularandcorticalbonemineral
From Study From Study densitywere4.0%and8.0%,respectively.Thecross-sectional
areaofcorticalbonewasmeasuredusingathresholdofperi-
730Randomized 730Randomized
to Placebo 38(5.2%) 29(4.0%) to Calcium ostealandendostealbonedensityof710and169mg/cm3,re-
Deceased Deceased
spectively.TheStressStrainIndexwascalculatedastheprod-
611(83.7%) 617(84.5%) uctofthesectionmodulusandcorticaldensitynormalizedto
Finished Study Finished Study themaximalphysiologicalcorticaldensityofhumanbones(1200
mg/cm3)forthepolarmomentandthebendingmomentsin
thexandydirections,wheretheydirectionisthewidestpart
Figure1.Detailsoftherecruitmentprocedure.Finishedstudyindicatesthe oftheradiusandthexdirectionisperpendiculartothis.19
numberofpeopleintheplaceboandcalciumgroupswhoremainedinthe
studyfortheentire60months.
BIOCHEMICALMEASUREMENTS
denandpharmaceuticalconsumptionweresimilartodataob-
tainedfromwholepopulationsofthisage.9Informedconsent Serumintactparathyroidhormone(PTH)levelwasmeasured
wasobtained,andtheHumanRightsCommitteeoftheUniver- using an immunochemiluminometric method with intra-
sityofWesternAustralia,Perth,Australia,approvedthestudy. assayandinterassayCVsof3.6%and6.2%,respectively.20Total
serum25-hydroxyvitaminDlevelwasmeasuredusinganex-
BASELINEDEMOGRAPHICS tractiontechnique,followedbyacompetitivebindingassayus-
ingdilutedhumanserumthatmeasures25-hydroxycholecal-
ciferolandergocalciferollevelsequally.Intra-assayandinterassay
Aprevalentfracturewasrecordedifitoccurredaftertheageof
CVswere8%and16%,respectively.21
50years,wasduetominimaltraumaasdefinedbyfallingfrom
aheightoflessthan1m,andwasnotoftheface,skull,orpha-
langes(Table1).Thenumberofyearssincemenopausewas RANDOMIZATIONTOSTUDYTREATMENT
calculated for each patient using reported age at last men- ANDCOMPLIANCE
strualperiod,hysterectomyandovariectomy,oronsetofhot
flushes.Apositivesmokinghistorywasreportedifatleast1 Patientsreceivedcalciumcarbonatetablets,600mgtwiceper
cigaretteperdayhadbeensmokedfor3monthsorlongerat day(withmorningandeveningmeals),oridenticalplacebotab-
anytime.Dailyintakeofprotein,calcium,andalcoholwasde- lets(WyethConsumerHealthcare,BaulkhamHills,Australia).
terminedfromaself-administeredsemiquantitativefoodfre- Therandomizationlistwasproducedbygenerating150blocks
quencyquestionnaire.10,11 of10numbers.Ineachblock,5positionsrepresentingplacebo
and5positionsrepresentingcalciumtreatmentwereorderedus-
CLINICALMEASUREMENTS ingalettercodeaccordingtoarandomnumbergenerator.The
numberedblockswereorderedaccordingtorandomlygener-
Gripstrengthofthedominanthandwasrecordedasthehighest atednumbers,andanidentificationnumberwasassignedinor-
of3attempts12usingahandhelddynamometer(HandGripDy- dertoeachlettercodeintherandomizedlist.ThePharmacyDe-
namometer;TEC,Clifton,NJ).Bodymassindexwascalculated partmentoftheSirCharlesGairdnerHospital,Nedlands,Australia,
asweightinkilogramsdividedbythesquareofheightinmeters. assignedatreatmenttothelettercodeandassignedtheappro-
Activitylevelswerecalculatedinkilocaloriesperdayusing priatemedicationstothepatientaccordingtothislist.Theran-
avalidatedmethod13thatcombinesbodyweight,answersto domizationwasstratifiedbyallocatingpatientstoblocksac-
questionsonthenumberofhoursandtypeofphysicalactiv- cording to whether a prevalent nontraumatic fracture had
ity,andenergycostsofsuchactivities,14,15witharesponseof occurredafterage50years,ensuringthatanequalnumberof
nototheactivityquestionsresultingina0score. patientswithandwithoutaprevalentfracturereceivedplacebo
MobilityfunctioningwasmeasuredbythetimedUp&Go orcalcium.Medicationcompliancewascheckedbycountingre-
test,whichrequiredthatpatientsbetimedwhilegettingup, turnedtabletsateach12-monthreviewandwascalculatedasa
walking3m,turning,returningtothechair,andsittingdown percentageoftheoptimum.Averageyearlycomplianceofless
again.16ResultsofthestandingRhombergBalanceTest17were than80%wasclassifiedasnoncompliant.
classifiedastowhetherthepatientwasabletomaintainatan-
demstanceforatleast10seconds. INCIDENTFRACTURESANDADVERSEEVENTS
BONEMEASUREMENTS Adverseeventsresultinginattendancetoahealthcareprofes-
sionalwererecordedinadiaryat4-monthintervalsandcoded
Calcanealquantitativeultrasonography(QUS)measurements using the International Classification of Primary Care, Ver-
oftheleftfootwereobtainedusinganultrasounddensitom- sion2-Plus,systemdatabaseofdiseasecoding(FamilyMedi-
eter(LunarAchilles;GELunarCorp,Madison,Wis)atbase- cineResearchUnit,DepartmentofGeneralPractice,Univer-
lineand5years;thecoefficientsofvariation(CV)forspeedof sityofSydney,Sydney,Australia).Adverseeventsweregrouped
soundandbroadbandultrasoundattenuationwere0.43%and accordingto17categoriesidentifiedbytheInternationalClas-
1.59%,respectively.Dualx-rayabsorptiometry(DXA)boneden- sification of Primary Care, Version 2-Plus, system.22 Atrau-
(REPRINTED)ARCHINTERNMED/VOL166, APR24,2006 WWW.ARCHINTERNMED.COM
870
©2006AmericanMedicalAssociation.Allrightsreserved.
Downloaded From: http://archinte.jamanetwork.com/ by a Fudan University User on 05/11/2015
Table1.BaselineDetailsoftheSubjectsbyComplianceandTreatment*
PatientsCompliantWithMedication PatientsNoncompliantWith PValue
RegimenbyTreatment MedicationRegimenbyTreatment Between
Compliance
Characteristic Placebo Calcium Placebo Calcium Groups
DemographicData
No.ofsubjects 410 420 320 310
Age,y 75.1±2.7 74.9±2.5 75.2±2.8 75.6±2.9 .006
Timesincemenopause,mean(range),y 26(23-31) 26(22-29) 26(23-31) 27(24-29) .02
Weight,kg 68.7±12.2 68.7±12.1 68.8±12.5 68.4±14.0 .43
Height,cm 158.7±6.0 159.1±5.8 158.2±6.0 159.3±6.0 .95
Prevalentfracturessinceage50y,%† 25.2 26.2 31.6 27.7 .09
Smokedever,%‡ 34.2 36.1 37.2 42.2 .09
Recreationalactivity,% 75 76 73 76 .57
TimedUp&Gotest,s 9.6±2.6 9.7±2.3 10.5±3.7 10.7±3.5 .001
Gripstrength,kg 20.8±4.5 20.6±4.7 20.0±4.7 20.0±4.7 .002
PassedRhombergBalanceTest,% 76.6 74.3 70.8 69.8 .006
FoodFrequencyAnalysis
No.ofsubjects 390 400 302 293
Proteinintake,mean(interquartilerange),g/d 76(60-94) 78(62-97) 76(77-93) 77(76-95) .10
Calciumintake,mean(interquartilerange),mg/d 897(704-1146) 915(711-1196) 950(761-1173) 903(685-1146) .46
Alcoholconsumption,%§ 19 22 27 19 .31
HeelQUS
No.ofsubjects 394 407 304 296
BUA,dB/MHz 100.5±8.2 101.1±7.9 99.6±8.1 100.3±7.5 .046
SOS,m/s 1514±26 1515±24 1510±27 1511±26 .004
HeelQUSstiffness,%ofthatofyoungadult 70.8±11.7 71.6±11.0 69.2±11.7 69.9±11.2 .007
HipDXABMD||
No.ofsubjects 361 352 198 188
TotalhipBMD,mg/cm2 817±120 819±123 813±119 818±122 .17
FemoralneckBMD,mg/cm2 692±98 695±102 693±114 680±111 .29
Whole-BodyBMD¶
No.ofsubjects 120 98 44 46
Whole-bodyBMD,mg/cm2 866±91 863±102 861±114 835±80 .17
Abbreviations:BMD,bonemineraldensity;BUA,broadbandultrasoundattenuation;DXA,dualx-rayabsorptiometry;QUS,quantitativeultrasonography;
SOS,speedofsound.
*Unlessotherwiseindicated,dataareexpressedasmean±SD.
†Indicatespercentageofthepatientswith1ormoreprevalentfractureafter50yearsofage.
‡Indicatespercentageofpatientswhoreportedsmoking1cigaretteperdayforatleast3months.
§Indicatesmorethan2standarddrinks/week.
||Measuredat1year.
¶Excludesthehead.
maticincidentclinicalfracturesandatraumaticsymptomatic clinicaleventwasanalyzedusingtheCoxproportionalhaz-
vertebralfractureswerereportedinthediary.Thediagnosis ardsmodelwithandwithoutadjustmentforcovariates.Dif-
andclassificationofvertebralandnonvertebralfractureswere ferencesbetweennormallydistributedcharacteristicsofthetreat-
confirmedbyradiographicreports. mentgroupsweredeterminedbyunivariateanalysisofvariance
Vertebraldeformitieswereassessedusingmorphometric withadjustmentsforcovariates.TheMann-Whitneytestwas
x-rayabsorptiometrysoftwareonadensitometer(softwarever- usedtodeterminethedifferencesbetweenthegroupsfornon-
sion9.1,Hologic4500A;HologicCorp)atyears1and5.The normallydistributedvariables.Allstatisticaltestswere2-tailed,
positionsof6referencemarkersforeachvertebrawereplaced andP(cid:1).05wasconsideredsignificant.
atthecornersandinthemiddleoftheupperandlowersurface Powercalculationswereconductedbeforestudycommence-
ofeachvertebra.ThemeanCVsinmorphometricx-rayabsorp- ment,assumingafracturerateof3.5%peryearintheplacebo
tiometrymeasurementsoftheanterior,middle,andposterior groupandassumingthatcalciumwouldreducetheeventrate
heightsofvertebraevariedfrom5.8%atT6to3.1%atL4.Ver- by35%.Atapowerofatleast80%,atan(cid:2)of.05,andallowing
tebralheightsreferencedataandvaluesfordeformitieswerecal- fora30%noncompliancerateduringthe5-yearstudy,recruit-
culatedaccordingtoamodificationoftheproceduredescribed mentof737patientspergroupwasrequired.
byMcCloskeyetal.23Incidentvertebraldeformitieswerede-
finedasvertebraldeformitiesnotpresentatyear1,withare-
RESULTS
ductioninposterior,middle,oranteriorheightsof20%ormore.
STATISTICSANDPOWERCALCULATIONS Patientrecruitmentforthestudyandtheirfinalcategori-
zation is shown in Figure 1. Of the 1222 women ex-
StatisticalprocedureswereperformedwithSPSSPCforWin- cluded,977(80.0%)weretakingmedicationsthatcould
dowsversion11.5(SPSS,Inc,Chicago,Ill).Thetimetofirst affectbonemass,199(16.3%)hadmedicalconditionsthat
(REPRINTED)ARCHINTERNMED/VOL166, APR24,2006 WWW.ARCHINTERNMED.COM
871
©2006AmericanMedicalAssociation.Allrightsreserved.
Downloaded From: http://archinte.jamanetwork.com/ by a Fudan University User on 05/11/2015
Therisksofwithdrawalanddeathwerethesamein
Table2.PatientsSustaining1orMoreIncidentFractures thecalciumgroup(hazardratio[HR],0.86;95%confi-
orVertebralDeformitiesDuring60Months
denceinterval[CI],0.63-1.16)comparedwiththepla-
attheSkeletalSitesShown
cebo group (HR, 0.76; 95% CI, 0.47-1.23) (Figure 1).
Eighthundredthirtypatients(56.8%)compliedwiththe
No.(%)ofPatients
medicationregimenthroughoutthestudy,withnosig-
byTreatment
nificantdifferenceincompliancefailureinthecalcium
Variable Placebo Calcium HR(95%CI) group(310patients)comparedwiththeplacebogroup
Allsubjects(N=1460)
(320patients)((cid:3)2=0.28;P=.60).Comparedwithcom-
Upperlimb 31(4.2) 29(4.0) 0.93(0.56-1.54) pliantpatients,noncompliantpersonswereslightlyolder,
Wristorhand 20(2.7) 21(2.9) 1.10(0.60-2.02) weaker, and slower and had lower QUS measures
Riborpelvis 17(2.3) 17(2.3) 0.99(0.55-1.78)
(Table 1), but there were no differences related to the
Proximalfemur 6(0.8) 11(1.5) 1.84(0.68-4.96)
originalrandomizationtocalciumorplacebo.
Lowerlimb 31(4.2) 18(2.5) 0.58(0.32-1.03)
Anyappendicularsite 94(12.9) 83(11.4) 0.88(0.65-1.18)
Spine 39(5.3) 38(5.2) 0.98(0.63-1.54) INCIDENTFRACTURE
Anysite 126(17.3) 110(15.1) 0.87(0.67-1.12)
Vertebraldeformity* 50(11.1) 44(10.2) 0.95†(0.78-1.17) Table 2 and Figure 2 show the fracture outcomes. A
(n=883)
total of 236 individuals (16.2%) sustained 297 incident
Compliantwithmedication
osteoporoticfractures.Theintention-to-treatanalysisdid
(n=830)
Upperlimb 22(5.4) 10(2.4) 0.44(0.21-0.92) notdemonstrateaneffectofcalciumtoreducefracturerisk,
Wristorhand 12(2.9) 10(2.4) 0.81(0.35-1.88) recordedastimetofirstfractureatanysite(HR,0.87;95%
Riborpelvis 13(3.2) 8(1.9) 0.71(0.33-1.55) CI,0.67-1.12),timetofirstfractureoftheappendicular
Proximalfemur 3(0.7) 5(1.2) 1.64(0.39-6.87) skeleton(HR,0.88;95%CI,0.65-1.18),timetofirstver-
Lowerlimb 18(4.4) 10(2.4) 0.54(0.25-1.18)
tebralfracture(HR,0.98;95%CI,0.63-1.54),orincident
Anyappendicularsite 58(14.1) 39(9.3) 0.65(0.43-0.97)
morphometricx-rayabsorptiometryvertebraldeformity.
Spine 8(2.0) 9(2.1) 1.10(0.42-2.84)
Anysite 63(15.4) 43(10.2) 0.66(0.45-0.97) Apreplannedperprotocolanalysisrestrictedtothe
Vertebraldeformity* 32(10.5) 22(7.2) 0.83†(0.65-1.05) 830 patients (56.8%) who consumed 80% of tablets
(n=609) (Figure2andTable2)demonstratedareductioninall-
Noncompliantwith siteclinicalfractures(HR,0.66;95%CI,0.45-0.97),ap-
medication(n=630)
pendicularfractures(HR,0.65;95%CI,0.43-0.97),and
Upperlimb 9(2.8) 19(6.1) 2.17(0.98-4.80)
upper limb fractures (HR, 0.44; 95% CI, 0.21-0.92) in
Wristorhand 8(2.5) 11(3.5) 1.54(0.63-3.78)
Riborpelvis 4(1.3) 9(2.9) 1.59(0.62-4.10) thecalciumgroupbeforeandafteradjustmentforage,
Proximalfemur 3(0.9) 6(1.9) 2.01(0.50-8.05) body mass index, and prevalent baseline fracture en-
Lowerlimb 13(4.1) 8(2.6) 0.62(0.26-1.49) teredascovariates.Baselinedietarycalciumintakedid
Anyappendicularsite 36(11.3) 44(14.2) 1.27(0.82-1.98) notinfluenceanyoftheHRsobtained.Althoughanaly-
Spine 31(9.7) 29(9.4) 0.95(0.58-1.59)
sisofthebaselinestructuralassessmentoftheskeleton
Anysite 63(19.7) 67(21.6) 1.09(0.77-1.54)
using heel QUS (broadband ultrasound attenuation or
Vertebraldeformity* 18(12.4) 22(17.1) 1.21†(0.84-1.73)
(n=97) speedofsound)adjustedfortreatmentstatusshowedthat
individualswithhighermeasurementshadreducedin-
Abbreviations:CI,confidenceinterval;HR,hazardratio. cident fracture risk (HR per 1-SD increase in speed of
*Indicatesincidentvertebraldeformitiesassessedusingmorphometric sound, 0.67; 95% CI, 0.58-0.77; HR per 1-SD increase
x-rayabsorptiometryatyears1and5.
inbroadbandultrasoundattenuation,0.70;95%CI0.61-
†Expressedasrelativerisk.
0.80),theadditionofbaselineQUSbonestructuralmea-
suresdidnotsubstantiallyalteranyofthefractureHRs
examined.
madeitunlikelytheywouldsurvivethe5yearsofthestudy, Ananalysisoffracturesinthenoncompliantpopula-
44(3.6%)wereparticipatinginanotherclinicaltrial,and tionshowednodifferenceinthenumberortypeoffrac-
2(0.2%)werenotpreparedtobeassignedtotheplacebo. tures sustained between placebo- and calcium-treated
Another1580individualswerenotinterested.Therefore, patients.
1510womenwereeligibleforthestudy,ofwhomthefirst
1460wererecruited.Therewerenodifferencesinbase- BONESTRUCTUREANDBIOCHEMISTRY
linedemographiccharacteristicsbetweentheplaceboand
calciumgroups.Inarandomlyselectedsubsetofpatients Therewasnodifferenceinanybonefactorsbetweencal-
(n=81),25-hydroxyvitaminDlevelsweregenerallyabove cium-andplacebo-treatedpatientsatbaseline(QUS)and
thedeficientrangebecauseonly6.1%(duringwinter)and 1year(DXA)(Table1).Thechangesinbonestructure
2.8%(duringsummer)ofpatientshadvitaminDconcen- are shown in Figure 3. The QUS measurements from
trationsbelow12ng/mL((cid:1)30nmol/L)(mean±SDwin- baseline to 5 years, adjusted for body mass index, age,
terlevel,27±14ng/mL[67±35nmol/L];mean±SDsum- andtabletcompliance,showsignificantimprovementin
mer level, 35±12 ng/mL [87±30 nmol/L]). No PTH calcium-treated patients for broadband ultrasound at-
concentrations were above the upper limit of the refer- tenuationandstiffness,butnotspeedofsound.Areduc-
ence range (mean±SD winter level, 37±11 pg/mL; tion in the loss of bone content and area but not bone
mean±SDsummerlevel,37±11pg/mL;n=81). mineraldensitywasseenatthefemoralneckandwhole-
(REPRINTED)ARCHINTERNMED/VOL166, APR24,2006 WWW.ARCHINTERNMED.COM
872
©2006AmericanMedicalAssociation.Allrightsreserved.
Downloaded From: http://archinte.jamanetwork.com/ by a Fudan University User on 05/11/2015
bodysitesbutnototherhipsites,inthecalcium-treated
patients before and after adjustment for body mass in- Intention to Treat (n = 1460)
dex, age, and tablet compliance during the study. The 1.00 Censored for Death or Withdrawal From Study
cross-sectional radius peripheral quantitative com-
putedtomographydatameasuredat5yearsshowalarger
corticalvolumeinthecalciumgroupcomparedwiththe
placebogroup,whichhadafavorableeffectonthebone 0.95
strengthfactorsofthepolarStressStrainIndexandStress
StrainIndexinthexandydirections.
ThePTHleveldecreasedfrombaselinetoyear5(107
0.90
placebo-and103calcium-treatedpatients)inthecalcium
compared with the placebo group (mean ± SD change,
−8.9±13.2and−2.0±13.2pg/mL,respectively;P(cid:1).001).
0.85
ADVERSEEVENTS
Of the 92000 adverse events recorded, only constipa-
0.80
tionwashigherinthecalciumgroup(13.4%)compared
with the placebo group (9.1%), with no difference be-
tweengroupsinthepercentageofpatientswhostopped
studymedicationtherapybecauseofconstipation.Two
patientsineachtreatmentgrouphadkidneystonesdur-
ingthestudy.Incidentischemicheartdiseasewasdiag-
nosedin56patients(7.7%)inthecalciumgroupandin
51patients(7.0%)intheplacebogroup,withnodiffer-
enceintherelativeriskforthecalciumcomparedwith
placebogroup(HR,1.12;95%CI,0.77-1.64).
COMMENT
Thepatientsrecruitedforthestudywererepresentativeof
non–vitaminD–deficientambulatorywomenolderthan70
yearswhohavea5-yearriskoffracturegreaterthan15%.
The principal finding was that randomization to a cal-
ciumsupplementfor5yearsfailedtoshowasignificant
preventiveeffectonfracture,withresultssimilartothose
ofapreviousmeta-analysis24ofanumberofsmallstudies
ofappendicularfracture(relativerisk,0.86;95%CI,0.67-
1.12)andarecentlyreportedstudy25ofpatientswithapre-
viousfracture(HR,0.94;95%CI,0.81-1.09).Theyaredi-
vergentfrompreviousreports26,27ofbeneficialeffectsof
combinedcalciumandcholecalciferol(vitaminD)treat-
mentinpatientswhomayhavebeenvitaminDdeficient
andstudies28,29showingareductioninspinefracturewith
calciumsupplementationinosteoporoticpatients.
Thelackofsignificanceofcalciumtherapyinthein-
tention-to-treatanalysisislikelyduetothelackofcom-
pliancewiththemedicationregimen,whichinthepower maintenanceoforimprovementinQUSandDXAmea-
calculationbeforecommencementofthestudywaspre- sureswithcalciumsupplementationsupportsaneffectto
dictedtobe30%,butwasinfact43%.Thisisalimitation improvebonemassandpossiblyarchitecture.Theperiph-
of the study but reflects the difficulties of implementa- eralquantitativecomputedtomographydatashowedthat
tionofpreventivehealthpracticeinallsuchstudies.An- theeffectofcalciumwasprincipallytomaintaincortical
otherpossiblecauseforthisrelativelackofefficacymay boneintheendocorticalarea.Attheradialsite,itwaspos-
bethatthevitaminDstatusofthepopulation,although sibletodemonstrateanincreaseincorticalvolumeand
substantially better than that encountered in studies in thereforemassandcalculatedresistancetotorsionaland
higherlatitudes,mayhavebeeninsufficienttoallowop- bending forces by calcium, an expected result of in-
timalabsorptionanddisposalofcalciumtotheskeleton. creasedcorticalbonemass.Thelackofeffectontrabec-
Intheper-protocolanalysisofthe56.8%ofpatientswho ularbonedensitywassurprisingbutmayrelatetoasub-
took80%ormoreoftheirassignedmedication,therisk stantiallydamagedtrabecularstructureintheseindividuals
ofanyclinicalosteoporoticfracturewasreducedbyafac- orasite-specificeffectofreducedboneresorptionviaef-
torof0.34(absoluteriskreduction,15.4%-10.2%).The fectsonreducingthePTHlevel.5Thiswassupportedby
erutcarF
tuohtiW
noitroporP
A
Calcium
Placebo
Compliant Patients (n = 830)
Censored for Death or Withdrawal From Study
1.00
0.95
0.90
0.85
0.80
0 10 20 30 40 50 60 70
Time, mo
erutcarF
tuohtiW
noitroporP
B
Figure2.Coxproportionalhazardsanalysisoftheoccurrenceofthefirst
incidentfractureinpatientstakingcalciumcomparedwithpatientstakingthe
placebo.A,Intention-to-treatanalysis,adjustingfortabletcompliance(hazard
ratio[HR],0.87;95%confidenceinterval[CI],0.67-1.12).Afterfurther
adjustmentforbodymassindex(BMI),age,andprevalentfractureoccurring
after50yearsofage,theHRwas0.86(95%CI,0.67-1.11);afteradjustment
forcalciumandtabletcomplianceinteraction,theHRwas0.60(95%CI,
0.30-1.01).B,Subsetanalysisofpatientsconsuming80%ormoreoftablets
(HR,0.66;95%CI,0.45-0.97).AfteradjustmentforBMI,age,andprevalent
fractureoccurringafter50yearsofage,theHRwas0.67(95%CI,0.45-0.99).
(REPRINTED)ARCHINTERNMED/VOL166, APR24,2006 WWW.ARCHINTERNMED.COM
873
©2006AmericanMedicalAssociation.Allrightsreserved.
Downloaded From: http://archinte.jamanetwork.com/ by a Fudan University User on 05/11/2015
2.5
2.0
1.5 ∗
1.0
0.5
0.0
–0.5
–1.0
Placebo Calcium
Placebo
Calcium
ourbiochemicaldatashowingsignificantsuppressionof hip DXA were not significant covariates in the fracture
PTHwithcalciumsupplementation. analysis.Thus,theeffectof1.2gofcalciumappearstobe
Inpatientscompliantwiththemedicationregimen,base- sufficientlylargetobeapplicabletocompliantindividu-
linedietarycalciumintake,baselineheelQUS,or1-year als,irrespectiveofdietarycalciumintake,withnosignifi-
zHM/Bd
,AUB
ni
egnahC
A
2.5
2.0
1.5 ∗
1.0
0.5
0.0
–0.5
–1.0
Placebo Calcium
% ,ssenffitS
ni
egnahC
erocS
tludA
gnuoY
naeM
3
2
1
0
–1
Placebo Calcium
sm
,SOS
ni
egnahC
100
50
0
–50
∗
–100
–150
–200
–250
Placebo Calcium
gm
,CMB
kceN
laromeF
ni
egnahC
B
10
5
0
–5
–10
–15
–20
–25
Placebo Calcium
2mc/gm
,DMB
kceN
laromeF
ni
egnahC
0.10
0.05
†
0.00
–0.05
–0.10
–0.15
–0.20
–0.25
Placebo Calcium
2mc
,aerA
kceN
laromeF
ni
egnahC
10
0
–10
–20
†
–30
–40
–50
Placebo Calcium
g ,CMB
ydoB-elohW
ni egnahC
C
4
2
0
–2
–4
–6
–8
–10
Placebo Calcium
2mc/gm
,DMB
ydoB-elohW
ni
egnahC
10
0
–10
–20
†
–30
–40
–50
Placebo Calcium
2mc
,aerA
ydoB-elohW
ni egnahC
250
‡
200
150 ‡
‡ 100
50
0
Polar SSI SSI x SSI y
Direction Direction
3mm
,ISS
D
300
250
200
150
100
∗
50
0
Trabecular Cortical
Area Area
2mm
,aerA
enoB
TCQp
700
600
500
400
300
200
100
0
Trabecular Cortical
BMD BMD
3mc/gm
,DMB
TCQp
Figure3.Effectsoftreatmentonbonestructuralvariables.Resultsareexpressedasmean±SEMafteradjustmentforbaselineage,baselinebodymassindex
(BMI;calculatedasweightinkilogramsdividedbythesquareofheightinmeters),andtabletcompliance.A,Changeinquantitativeultrasonography(QUS)ofthe
heelfrombaselinetoyear5.B,Changeinfemoralneckbonemineralcontent(BMC),area,andbonemineraldensity(BMD)fromyears1to5.C,Changein
whole-bodyBMC,area,andBMDfromyears1to5.D,Peripheralquantitativecomputedtomography(pQCT)findingsofthedistalforearmatyear5.Changesin
QUS,BMD,andpQCTfactorswereadjustedtoameanageof75years,meanBMIof27,andtabletcompliance.BUAindicatesbroadbandultrasoundattenuation;
SOS,speedofsound;SSI,StressStrainIndex.*P(cid:1).001.†P(cid:1).05.‡P(cid:1).01.
(REPRINTED)ARCHINTERNMED/VOL166, APR24,2006 WWW.ARCHINTERNMED.COM
874
©2006AmericanMedicalAssociation.Allrightsreserved.
Downloaded From: http://archinte.jamanetwork.com/ by a Fudan University User on 05/11/2015
cantmodifyingeffectofbaselinebonestructure.Todate, 4. PrinceRL,SmithM,DickIM,etal.Preventionofpostmenopausalosteoporosis.
studiesoftheeffectivenessofpharmacologicagentsother NEnglJMed.1991;325:1189-1195.
5. PrinceR,DevineA,DickI,etal.Theeffectsofcalciumsupplementation(milk
than hormone replacement therapy30 in reducing frac-
powderortablets)andexerciseonbonedensityinpostmenopausalwomen.
turerateshasbeenrestrictedtohigh-riskpopulationswith
JBoneMinerRes.1995;10:1068-1075.
lowDXAbonemineraldensity.31Whenpatientshavenot 6. ReidIR,AmesRW,EvansMC,GambleGD,SharpeSJ.Long-termeffectsofcal-
beenselectedonthebasisoflowDXAbonemassdensity, ciumsupplementationonbonelossandfracturesinpostmenopausalwomen:a
nohipfracturereductionhasbeenfound.32 randomizedcontrolledtrial.AmJMed.1995;98:331-335.
7. RiggsBL,O’FallonWM,MuhsJ,O’ConnorMK,KumarR,MeltonJ.Long-term
Theper-protocolanalysispotentiallyviolatedtheorigi-
effectsofcalciumsupplementationonserumparathyroidhormonelevel,boneturn-
nalrandomization.Comparedwithcompliantpatients,non- over,andbonelossinelderlywomen.JBoneMinerRes.1998;13:168-174.
compliantindividualswereslightlyolder,weaker,andslower 8. SirisES,ChenYT,AbbottTA,etal.Bonemineraldensitythresholdsforpharma-
andhadlowerQUSmeasures,buttheseeffectsdidnotop- cologicalinterventiontopreventfractures.ArchInternMed.2004;164:1108-1112.
9. BruceDG,DevineA,PrinceRL.Recreationalphysicalactivitylevelsinhealthyolder
eratedifferentiallyinthe2treatmentgroups.Wealsoevalu-
women:theimportanceoffearoffalling.JAmGeriatrSoc.2002;50:84-89.
ateddifferencesbetweentreatmentgroupsinfractureinthe
10. IrelandP,JolleyD,GilesG,etal.DevelopmentoftheMelbourneFFQ.AsiaPac
noncompliantpatientsinadditiontothecompliantpatients. JClinNutr.1994;1:19-31.
Theanalysisoffractureratesinthenoncompliantpatients 11. HodgeA,PattersonAJ,BrownWJ,IrelandP,GilesG.TheAntiCancerCouncil
showednodifferenceinriskoffracturerelatedtotreatment ofVictoriaFFQ.AustNZJPublicHealth.2000;24:576-583.
12. KallmanDA,PlatoCC,TobinJD.Theroleofmusclelossintheage-relatedde-
group,thusmakingitunlikelythatpatientshadbecome
clineofgripstrength.JGerontol.1990;45:M82-M88.
noncompliantowingtotreatmentstatus. 13. DevineA,DhaliwalSS,DickIM,BollerslevJ,PrinceRL.Physicalactivityandcal-
Becauseitisimportantforapublichealthinterven- ciumconsumptionareimportantdeterminantsoflowerlimbbonemassinolder
tiontobesafe,weconductedacarefulevaluationofad- women.JBoneMinerRes.2004;19:1634-1639.
14. McArdleWD,KatchFI,KatchVL.Energy,NutritionandHumanPerformance.Phila-
verseevents.Ourevaluationshowedthat,althoughcon-
delphia,Pa:Lea&Febiger;1991.
stipation increased with calcium treatment, the risk of
15. PollockML,WilmoreJH,FoxSM.HealthandFitnessThroughPhysicalActivity.
kidneystones,ischemicheartdisease,orotheradverse NewYork,NY:JohnWiley&SonsInc;1978.
eventswasnotincreased. 16. PodsiadloD,RichardsonS.Thetimed“Up&Go”:atestofbasicfunctionalmo-
Inconclusion,thecalciumsupplementationregimen bilityforfrailelderlypersons.JAmGeriatrSoc.1991;39:142-148.
17. GuralnikJM,FerrucciL,SimonsickEM,SaliveME,WallaceRB.Lower-
testedcurrentlycannotberecommendedasapublichealth
extremityfunctioninpersonsovertheageof70yearsasapredictorofsubse-
approach to fracture prevention because of the lack of quentdisability.NEnglJMed.1995;332:556-561.
long-termcompliance.Thesedatashouldgivepauseto 18. HenzellS,DhaliwalS,PontifexR,etal.Precisionerroroffan-beamdualX-ray
thosewhoconsiderthatpublichealthpolicyinthisarea absorptiometryscansatthespine,hip,andforearm.JClinDensitom.2000;
3:359-364.
should be based on epidemiological or surrogate end-
19. SchoenauE,NeuCM,RauchF,ManzF.Thedevelopmentofbonestrengthat
pointdata.However,thesedatasupportthecontinued
theproximalradiusduringchildhoodandadolescence.JClinEndocrinolMetab.
useofcalciumsupplementsbywomenwhoareableto 2001;86:613-618.
remaincompliantwiththeiruse.Intheseindividuals,es- 20. St.JohnA,DaviesC,RileyWJ,etal.Comparisonoftheperformanceandclini-
peciallyiftheyareunderthecareofaclinician,calcium calutilityofacarboxy-terminalassayandanintactassayforparathyroidhormone.
ClinChimActa.1988;178:215-223.
supplementation is a safe and effective therapy for re-
21. DeanB,KolavcicMS,WarkJD,HarrisonLC.ChromatographyofserumonSep-
ducingtheriskofosteoporoticfracture. pakC18correctsfalselyelevatedvitaminDmetabolitelevelsmeasuredbypro-
teinbindingassay.ClinChimActa.1988;176:169-178.
AcceptedforPublication:September11,2005. 22. BrittH.Anewcodingtoolforcomputerisedclinicalsystemsinprimarycare—
ICPCplus.AustFamPhysician.1997;26:S79-S82.
Correspondence:RichardL.Prince,MD,Departmentof
23. McCloskeyEV,SpectorTD,EyresKS,etal.Theassessmentofvertebraldeformity.
Endocrinology and Diabetes, First Floor C Block, Sir
OsteoporosInt.1993;3:138-147.
CharlesGairdnerHospital,Nedlands,WesternAustra- 24. SheaB,WellsG,CranneyA,etal.Meta-analysesoftherapiesforpostmeno-
lia,Australia6009(rlprince@cyllene.uwa.edu.au). pausalosteoporosis,VII:meta-analysisofcalciumsupplementationforthepre-
AuthorContributions:DrsPrince,Devine,andDickhad ventionofpostmenopausalosteoporosis.EndocrRev.2002;23:552-559.
25. GrantAM,AvenellA,CampbellMK,etal.OralvitaminD andcalciumforsec-
fullaccesstoallthedatainthestudyandtakerespon- 3
ondarypreventionoflow-traumafracturesinelderlypeople(RandomisedEvalu-
sibilityfortheintegrityofthedataandtheaccuracyof ationofCalciumorVitaminD,RECORD).Lancet.2005;365:1621-1628.
thedataanalysis. 26. ChapuyMC,ArlotMF,DuboeufF,etal.VitaminD andcalciumtopreventhip
3
FinancialDisclosure:None. fracturesinelderlywomen.NEnglJMed.1992;327:1637-1642.
27. Dawson-HughesB,HarrisSS,KrallEA,DallalGE.Effectofcalciumandvitamin
Funding/Support: This study was supported by a re-
Dsupplementationonbonedensityinmenandwomen65yearsofageorolder.
searchgrantfromtheHealthwayHealthPromotionFoun-
NEnglJMed.1997;337:670-676.
dationofWesternAustraliaandbyprojectgrant254627 28. ReckerRR,HindersS,DaviesKM,etal.Correctingcalciumnutritionaldefi-
fromtheNationalHealthandMedicalResearchCoun- ciencypreventsspinefracturesinelderlywomen.JBoneMinerRes.1996;
cilofAustralia. 11:1961-1966.
29. RiggsBL,SeemanE,HodgsonSF,TavesDR,O’FallonWM.Effectofthefluoride/
Disclaimer:Neitherofthefundingagencieshadanyinput
calciumregimenonvertebralfractureoccurrenceinpostmenopausalosteoporosis.
intoanyaspectofthedesignandmanagementofthisstudy. NEnglJMed.1982;306:446-450.
30. BaggerYZ,TankoLB,AlexandersenP,etal.Twotothreeyearsofhormonere-
placementtreatmentinhealthywomenhavelong-termpreventiveeffectsonbone
REFERENCES
massandosteoporoticfractures:thePERFstudy.Bone.2004;34:728-735.
31. CummingsSR,BlackDM,ThompsonDE,etal.Effectofalendronateonriskof
1. PrinceRL.Counterpoint:estrogeneffectsoncalcitropichormonesandcalcium fractureinwomenwithlowbonedensitybutwithoutvertebralfractures:results
homeostasis.EndocrRev.1994;15:301-309. fromtheFractureInterventionTrial.JAMA.1998;280:2077-2082.
2. ChristakosS,PrinceR.Estrogen,vitaminD,andcalciumtransport.JBoneMiner 32. McClungMR,GeusensP,MillerPD,etal;HipInterventionProgramStudyGroup.
Res.2003;18:1737-1739. Effectofrisedronateontheriskofhipfractureinelderlywomen.NEnglJMed.
3. NordinBEC.Calciumandosteoporosis.Nutrition.1997;13:664-686. 2001;344:333-340.
(REPRINTED)ARCHINTERNMED/VOL166, APR24,2006 WWW.ARCHINTERNMED.COM
875
©2006AmericanMedicalAssociation.Allrightsreserved.
Downloaded From: http://archinte.jamanetwork.com/ by a Fudan University User on 05/11/2015
